Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...

The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...

The focus on treating people who have no cognitive impairment raises questions about how to implement testing for those at ...

After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...

The trial will include patients with relapsed or refractory B-cell malignancies, including patients who have received prior CAR T-cell therapies.

Telix Pharmaceuticals has opened a new radiopharmaceutical manufacturing and treatment facility in Melbourne, Australia, the company announced Thursday. Telix said the integrated facility in Melbourne ...

In an investigator-initiated trial, researchers will evaluate TPST-4003 in autoimmune disorders like myasthenia gravis and multiple sclerosis.

The results presented at AAIC had been highly anticipated since Biogen said it would advance the drug despite missing a Phase ...